Introduction
cells and tissues. Of these, the superoxide dismutases I (CuZnSOD), II (MnSOD) and III (extracellular SOD
) are of utmost importance. Although CuZnSOD and MnSOD provide intracellular and intramitochondrial protection against superoxide, respectively, ecSOD does so in the interstitium. It is expressed in vascular smooth muscle cells and is subsequently secreted to the interstitium [5] . It binds to polyanionic sites such as heparin sulphates at the outer membrane of endothelial cells and likely protects endothelial nitric oxide while it traverses to the smooth muscle cell layer of the vascular wall [6] . The highest ecSOD concentrations are found between the endothelial cell layer and the smooth muscle, and 99% of ecSOD is tissue-bound. [7] . Hence, driving the expression of ecSOD appears to be an important mechanism underlying the antioxidative effects of nitric oxide. We have also found in several studies that the nitric oxide donors such as pentaerythritol tetranitrate (PETN) [8, 9] and isosorbide mononitrate [10] [11] .
Previous investigations have shown that endogenous nitric oxide is an essential stimulus of ecSOD expression in large conductance vessels such as the aorta, and that an increase of endothelial (e)NOS expression by exercise results in a consecutive overexpression of ecSOD

exert substantial anti-atherosclerotic effects in rabbits, as demonstrated by a reduction in aortic plaque load, an improvement of endothelial function and a reduction of vascular superoxide production. One experimental study reported that PETN increases vascular haemoxygenase expression by approximately 1.5-fold, and it is likely that such a mechanism may play a role in the anti-atherosclerotic effects of PETN
The aim of this study was to investigate whether PETN can increase ecSOD expression and activity in the microvasculature and whether such effects are induced by endogenous nitric oxide, as generated by endothelial-specific overexpression of eNOS as well. 
Materials and methods
C57BL/6 mice
Measurement of blood pressure
Systolic blood pressure and heart rate were measured in awake male eNOS ϩϩ (n ϭ 6) and eNOS n (n ϭ 6) mice at 3-4 months of age using an automated tailcuff system (Visitech Systems, Apex, NC, USA), as described previously [14] . 
Western blot
Preparation of cytosols from mouse lungs was performed as described previously [15] . 
Measurement of ecSOD activity
The lungs were homogenized in 50 mM potassium phosphate (pH 7.4) containing 0.3 mol/l potassium bromide, as described previously [16] . Chromatography of homogenates on concanavalin A sepharose (GE Healthcare, Uppsala, Sweden) has been used to separate ecSOD from other SOD isoenzymes [16] . The SOD activity was determined spectrophotometrically by monitoring the inhibition of the rate of xanthine oxidasemediated reduction of cytochrome C, as described previously [17] . Fig 3A) .
Statistics
All data were analysed by a standard computer program (GraphPad Prism PC software, version 3.03, Graphpad Software, La Jolla, CA, USA) and are expressed as mean Ϯ S.E.M. of n individual samples. Statistical comparisons between the groups were performed by either the t-tests or the Newman-Keuls multiple comparisons test following one-way analysis of variance (ANOVA). P Ͻ 0.05 was considered statistically significant.
Results
PETN metabolites and blood pressure data
A comparable result was obtained with a polyclonal ecSOD antibody (data not shown). A post-hoc analysis revealed statistical significance for PETN-60 versus PETN-0 but not for PETN-6
versus PETN-0 (Fig. 3A) . Similar data were obtained in the aortas of the PETN-treated mice (Fig. 3B) (Fig. 3D) .
ecSOD activity
Changes in ecSOD activity paralleled changes in ecSOD expression (n ϭ 7, P Ͻ 0.0001, ANOVA; Fig 4A) Fig. 4B ).
Fig. 1 eNOS and blood pressure in eNOS-overexpressing mice. (A) Blood pressure in C57Bl/6 mice before (initial) and after treatment with PETN (not significant). (B) Untreated eNOS ϩϩ mice have a significant lower blood pressure than eNOS n (* ϭ P Ͻ 0.05). After 25 days of treatment with the eNOS inhibitor L-NA, this difference disappeared (P Ͼ 0.05). (C) Upper panel: Western blot for eNOS in aortic homogenates of eNOS ϩϩ
; lower panel (n ϭ 4): a mean of 2.8 Ϯ 0.5-fold greater eNOS expression than in eNOS
n (n ϭ 4, * ϭ P Ͻ 0.05).
Fig. 2 ecSOD mRNA levels. (A) Treatment of C57Bl/6 mice with 6 mg/kg/day (PETN-6) or 60 mg/kg/day (PETN-60) PETN induced no changes in lung ecSOD mRNA expression relative to HPRT (P Ͼ 0.05 versus PETN-0). (B) eNOS ϩϩ mice induced no changes in lung ecSOD mRNA expression relative to HPRT (P Ͼ 0.05 versus eNOS n ). (C) eNOS ϩϩ mice induced no changes in aortic ecSOD mRNA expression relative to SMA (P Ͼ 0.05 versus eNOS n ), irrespective of oral treatment
with L-NA. [18] . There is some debate whether nitric oxide is indeed the pharmacologically active principle of organic nitrates [19] [8] , and this effect was evident even in established atherosclerosis [9] . Further activities of PETN such as inhibition of endothelial dysfunction and LDL oxidation are consistent with an inhibition of superoxide formation as well [9] , although it is not sure that the observed effect is active in a similar manner in pathological settings. Additionally, PETN does not induce the development of in vivo nitrate tolerance [18] , which strikingly contrasts the effect of glyceryl trinitrate, which is a well-known inducer of nitrate tolerance associated with increased vascular oxidative stress [33] . The lack of nitrate tolerance induction by PETN was shown in experimental [26, 34] and clinical studies [35] . Hence [36] [37] [38] . However, superoxide is rapidly detoxified to hydrogen peroxide, which has been shown to induce both the expression and the activity of eNOS [39] . Thus, a higher activity of ecSOD will not only reduce extracellular superoxide but also protect readily formed nitric oxide. By increasing hydrogen peroxide, it most likely increases endothelial nitric oxide synthesis as well. This effect of hydrogen peroxide has been shown to contribute to the up-regulation of vascular nitric oxide synthesis induced by exercise training [12] .
Fig. 3 ecSOD protein expression. (A) Increased ecSOD protein expression in lung cytosolic fractions of C57Bl/6 mice treated with 0, 6 or 60 mg/kg/day PETN (PETN-0, PETN-6 or PETN-60, respectively, * ϭ P Ͻ 0.05 for PETN-60 versus PETN-0). (B) Increased ecSOD protein expression in aortic homogenates of PETN-treated mice (* ϭ P Ͻ 0.01 versus PETN-0). (C) Increased ecSOD protein expression in lung cytosols of eNOS
Discussion
The aim of this study was to investigate whether vascular expression of ecSOD is subject to genetic and pharmacological regulation. Our findings are that the organic nitrate PETN increases the expression and activity of microvascular and macrovascular ecSOD in mice in vivo, and that a similar increase was observed in untreated transgenic mice with an endothelium-specific overexpression of bovine eNOS. These data extend previous observations and suggest that increased bioavailability of vascular nitric oxide regulates ecSOD expression, and that this effect might contribute to the antioxidative and anti-atherosclerotic effects of PETN observed previously. This is the first study that demonstrates that PETN can induce the expression of ecSOD. PETN is an organic nitrate that is known to exert its anti-anginal effect by nitric oxide-dependent activation of soluble guanylyl cyclase (sGC), subsequent cyclic guanosine monophosphate (cGMP)-induced activation of protein kinase G and vasodilation of conductive arteries
